Monday, March 14, 2011

Impax late-stage Parkinson's Disease drug works well in study

A treatment for Parkinson’s Disease being developed by Impax Laboratories Inc. did well in a Phase III clinical trial.
The Hayward company (NASDAQ: IPXL) said Monday that the drug, IPX066, an extended release treatment, performed well compared against an immediate release version of the same compound.

No comments:

Post a Comment